elranatamab + teclistamab

**Elranatamab + teclistamab** is an investigational combination of two BCMA-targeting bispecific T-cell engagers for relapsed/refractory multiple myeloma (RRMM). Both drugs are FDA-approved BCMA x CD3 bispecific antibodies that redirect T cells to lyse BCMA-expressing myeloma cells, with elranatamab (Pfizer) using flat dosing and teclistamab (Janssen) using weight-based dosing, both administered subcutaneously after step-up doses to mitigate cytokine release syndrome (CRS). The combination is being explored in clinical trials to enhance efficacy in heavily pretreated patients, potentially overcoming resistance mechanisms seen with monotherapy, though specific trial data on this exact pairing is limited compared to other dual bispecific regimens like teclistamab + talquetamab.[1][11]